Literature DB >> 29729949

Prevention of Glucocorticoid-Induced Osteoporosis: Clinical audit to evaluate the implementation of National Osteoporosis Guideline Group 2017 guidelines in a primary care setting.

Matthew Carter1.   

Abstract

Treatment with glucocorticoids is the leading cause of drug-induced osteoporosis. National Osteoporosis Guideline Group (NOGG) 2017 guidelines advise a case-finding strategy for patients at risk. The aims of the audit were to evaluate the implementation of the NOGG 2017 guidelines for patients receiving long-term glucocorticoid therapy in a suburban general practice, to instigate changes to ensure 90% of patients are investigated and treated appropriately, and to evaluate impact at a 6-mo re-audit. Reporting Analysis and Intelligence Delivering Results (RAIDR) is a health-care intelligence tool accessing primary care clinical data. Using RAIDR, data on relevant osteoporotic risk factors were combined to produce FRAX scores for patients who had been prescribed glucocorticoids 3 or more times in the past 12 months. FRAX data were displayed in a NOGG guidance graph for major osteoporotic fracture probability. Patients were assessed as high, intermediate, or low risk. High- and intermediate-risk patients above the NOGG threshold were recommended to start bisphosphonates; these patients were sent a prescription for alendronate and a letter of explanation. There were no intermediate patients below the NOGG threshold. Low-risk patients were recommended to have lifestyle advice; a leaflet was produced and sent to these patients. Initial results showed that only 25% of patients recommended to be on bisphosphonates were taking them. Steps were taken to educate the general practitioners in the FRAX tool and NOGG guidelines; the chronic obstructive pulmonary disease annual template was amended to aid adherence by alerting the nurse to the number of glucocorticoid courses prescribed, with additional boxes for prescribing alendronate and printing the lifestyle leaflet; and 2-monthly RAIDR searches by the practice pharmacist were started. A re-audit 6 mo later showed improvement to 92%. This audit showed that education, reminders, and simple computer prompts can greatly improve the implementation of NOGG guidelines for glucocorticoid-induced osteoporosis.
Copyright © 2018 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  glucocorticoid; guidelines; osteoporosis

Mesh:

Substances:

Year:  2018        PMID: 29729949     DOI: 10.1016/j.jocd.2018.03.009

Source DB:  PubMed          Journal:  J Clin Densitom        ISSN: 1094-6950            Impact factor:   2.617


  5 in total

Review 1.  Prevention and Treatment of Glucocorticoid-Induced Osteoporosis in Adults: Consensus Recommendations From the Belgian Bone Club.

Authors:  Michaël R Laurent; Stefan Goemaere; Charlotte Verroken; Pierre Bergmann; Jean-Jacques Body; Olivier Bruyère; Etienne Cavalier; Serge Rozenberg; Bruno Lapauw; Evelien Gielen
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

Review 2.  UK clinical guideline for the prevention and treatment of osteoporosis.

Authors:  Celia L Gregson; David J Armstrong; Jean Bowden; Cyrus Cooper; John Edwards; Neil J L Gittoes; Nicholas Harvey; John Kanis; Sarah Leyland; Rebecca Low; Eugene McCloskey; Katie Moss; Jane Parker; Zoe Paskins; Kenneth Poole; David M Reid; Mike Stone; Julia Thomson; Nic Vine; Juliet Compston
Journal:  Arch Osteoporos       Date:  2022-04-05       Impact factor: 2.879

3.  Implementation of recommendations for prevention of glucocorticosteroid-induced osteoporosis in hospitalized patients.

Authors:  Tal Gazitt; Muna Elias; Joy Feld; Idit Lavi; Amir Haddad; Rema Bishara-Garzuzi; Muhanad Abu Elhija; Adi Kibari; Devy Zisman
Journal:  Clin Rheumatol       Date:  2021-06-22       Impact factor: 2.980

4.  Evaluation of risk factors of vertebral fracture in Japanese female patients with glucocorticoid-induced osteoporosis.

Authors:  Yu Mori; Takuya Izumiyama; Kazuyoshi Baba; Naoko Mori; Hiroshi Fujii; Tomonori Ishii; Eiji Itoi
Journal:  J Orthop Surg Res       Date:  2020-07-29       Impact factor: 2.359

Review 5.  When to Start and Stop Bone-Protecting Medication for Preventing Glucocorticoid-Induced Osteoporosis.

Authors:  Kaleen N Hayes; Ulrike Baschant; Barbara Hauser; Andrea M Burden; Elizabeth M Winter
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-15       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.